Clinical trials: Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing…
- Trial name
- DEW (NCT07831928)
- Testing
- Online wellness course and online exercise platform, Usual Care Group
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Iowa
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06677710
- Testing
- IDP-023, Ocrelizumab, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Indapta Therapeutics, INC.
Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS)
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3.
- Conditions
- Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary-progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- INsIDER (NCT05177523)
- Testing
- MRI, Neurocognitive examination for healthy subjects, blood sampling
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland